NASDAQ:SYBXSynlogic Stock Price, Forecast & News

Synlogic's stock was trading at $1.54 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, SYBX shares have increased by 58.4% and is now trading at $2.44. View which stocks have been most impacted by Coronavirus.

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Synlogic in the last year. There are currently 1 sell rating, 1 hold rating and 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Synlogic.

Synlogic is scheduled to release its next quarterly earnings announcement on Thursday, August 13th 2020. View our earnings forecast for Synlogic.

Synlogic Inc (NASDAQ:SYBX) issued its quarterly earnings results on Friday, May, 8th. The biotechnology company reported ($0.46) earnings per share for the quarter, missing the Zacks' consensus estimate of ($0.43) by $0.03. The biotechnology company had revenue of $0.10 million for the quarter, compared to the consensus estimate of $0.73 million. Synlogic had a negative return on equity of 33.46% and a negative net margin of 2,733.25%. View Synlogic's earnings history.

Synlogic shares reverse split on Monday, August 28th 2017. The 1-7 reverse split was announced on Friday, August 25th 2017. The number of shares owned by shareholders was adjusted after the market closes on Friday, August 25th 2017. An investor that had 100 shares of Synlogic stock prior to the reverse split would have 14 shares after the split.

6 brokerages have issued 1 year price targets for Synlogic's stock. Their forecasts range from $2.00 to $25.00. On average, they anticipate Synlogic's share price to reach $13.40 in the next twelve months. This suggests a possible upside of 449.2% from the stock's current price. View analysts' price targets for Synlogic.

Media stories about SYBX stock have been trending very positive on Wednesday, InfoTrie reports. InfoTrie identifies negative and positive news coverage by reviewing more than six thousand blog and news sources in real-time. The firm ranks coverage of companies on a scale of negative five to five, with scores closest to five being the most favorable. Synlogic earned a coverage optimism score of 4.0 on InfoTrie's scale. They also gave media headlines about the biotechnology company a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an impact on the company's share price in the immediate future. View the latest news aboutSynlogic.

Some companies that are related to Synlogic include Verastem (VSTM), Concert Pharmaceuticals (CNCE), Avid Bioservices (CDMO), Lannett (LCI), Neptune Wellness Solutions (NEPT), OrganiGram (OGI), Galera Therapeutics (GRTX), Chiasma (CHMA), Verrica Pharmaceuticals (VRCA), Mallinckrodt (MNK), Bicycle Therapeutics (BCYC), AMAG Pharmaceuticals (AMAG), Abeona Therapeutics (ABEO), Urovant Sciences (UROV) and CymaBay Therapeutics (CBAY). View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Synlogic investors own include Reata Pharmaceuticals (RETA), Approach Resources (AREX), Precision Drilling (PDS), First Financial Bankshares (FFIN), Corbus Pharmaceuticals (CRBP), Inovio Pharmaceuticals (INO), Sorrento Therapeutics (SRNE), Gilead Sciences (GILD), SCYNEXIS (SCYX) and Verastem (VSTM).

Synlogic trades on the NASDAQ under the ticker symbol "SYBX."

Synlogic's stock is owned by a number of institutional and retail investors. Top institutional investors include Two Sigma Investments LP (1.14%), JPMorgan Chase & Co. (1.14%), Two Sigma Advisers LP (0.99%), State Street Corp (0.93%), Geode Capital Management LLC (0.86%) and Parametric Portfolio Associates LLC (0.43%). Company insiders that own Synlogic stock include Paul Francis Miller and Richard P Shea. View institutional ownership trends for Synlogic.

SYBX stock was sold by a variety of institutional investors in the last quarter, including Morgan Stanley, Alambic Investment Management L.P., and Two Sigma Investments LP. View insider buying and selling activity for Synlogic.

SYBX stock was purchased by a variety of institutional investors in the last quarter, including Two Sigma Advisers LP, Parametric Portfolio Associates LLC, Los Angeles Capital Management & Equity Research Inc., Geode Capital Management LLC, Connor Clark & Lunn Investment Management Ltd., Wells Fargo & Company MN, JPMorgan Chase & Co., and State Street Corp. View insider buying and selling activity for Synlogic.

Shares of SYBX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of SYBX stock can currently be purchased for approximately $2.44.

Synlogic has a market capitalization of $80.13 million and generates $2.22 million in revenue each year. The biotechnology company earns $-51,370,000.00 in net income (profit) each year or ($1.70) on an earnings per share basis. Synlogic employs 74 workers across the globe.

The official website for Synlogic is www.synlogictx.com.

Synlogic's mailing address is 301 Binney St. Suite 402, Cambridge MA, 02142. The biotechnology company can be reached via phone at 617-401-9975 or via email at [email protected]